The Ocrelizumab group:In the Ocrelizumab group, subjects received a loading dose of 20mg of Ocrelizumab on Day 1, Day 7, and Day 14, followed by a subcutaneous injection of 20mg every 4 weeks.
Sponsors
Peking University People's Hospital
Conditions
Myasthenia gravis
Phase 2
A Study on the Efficacy and Safety of Ocrelizumab versus Tacrolimus in the Treatment of Newly Diagnosed Generalized Myasthenia Gravis Patients
Active, not recruitingChiCTR2400083801
Start: 2024-06-03Updated: 2024-12-02
Cancelled by the investigator. A Study on the Efficacy and Safety of Ocrelizumab in the Treatment of AchR Antibody Positive Generalized Myasthenia Gravis Patients
Active, not recruitingChiCTR2400083807
Start: 2024-06-02Updated: 2025-03-31